What Is Tumor Immunology?
June 15, 2026How Do Cancer Cells Evade the Immune System?
June 16, 2026Inside you is a cancer cell detection system — working every day, completely undetected by you
—— The tumor microenvironment: the underground tumors’ kingdom — and how to breach it.
I. How the immune system recognizes 'internal traitors'
Imagine you're in an airport needing to distinguish local travelers from suspicious foreigners. Your security strategy might include: checking passports (ID), observing whether behavior is abnormal (danger signals), checking whether they're carrying prohibited items (abnormal cargo). The immune system's logic for recognizing cancer cells is strikingly similar.
The problem is, cancer cells changed from your own cells — they're not foreign invaders, they're internal traitors who changed sides. This poses a puzzle for the immune system: how to precisely find cells that are going rogue without attacking normal cells? Evolution's answer is several complementary recognition systems. Each has its advantages and blind spots. Cancer cells need to circumvent all of these systems to truly survive and develop into tumors.
2. NK cells: recognizing problem cells through 'Missing Self'
NK cell recognition logic is built on an elegant principle: 'Missing Self.' Normal body cells all display MHC-I (Major Histocompatibility Complex class I molecules) on their surfaces — this is the cell's 'ID card,' telling the immune system 'I'm a normal cell of yours.' NK cells have a class of inhibitory receptors (KIR receptors) specifically recognizing MHC-I. When MHC-I signal is present, NK cells' inhibitory receptors are activated, and NK cells stand down, not attacking the cell.
But when cells become cancerous, they often downregulate or completely lose MHC-I expression — because cancer cells are trying to evade CD8+ T cell recognition. This strategy, while evading T cells, simultaneously triggers NK cells' alarm: 'This cell's ID is gone!' — NK cells launch an attack.
This is a sophisticated 'complementary surveillance' design: MHC-I high → T cells can recognize it, NK cells stand down; MHC-I low → T cells can't see it, but NK cells detect the anomaly and take over the attack. Cancer cells need to solve both problems simultaneously to escape this dual safety net.
3. 'Danger signals': the SOS broadcast from stressed cells
Beyond the passive signal of 'ID missing,' cells under cancer-induced stress also actively emit 'distress' signals. When cells experience DNA damage, oxidative stress, or other cellular stress (nearly inevitable during the cancer process), they upregulate a class of molecules on their surface called NKG2D ligands (like MICA, MICB, ULBP family). These molecules are almost unexpressed on normal cells but significantly increase on stressed cells — they're the cell saying: 'Something's wrong with me.'
NK cells and some T cells (γδ T cells) have NKG2D receptors specifically recognizing these 'distress' signals. Once the signal is received, NK cells are activated and launch attacks on the signaling cells. This system's design logic is to distinguish 'stressed abnormal cells' from 'resting normal cells' — not directly recognizing specific cancer markers. This makes it a very broad-spectrum initial alarm system.
4. T cells: precision hunting through 'tumor antigens'
NK cells are broad-spectrum rapid response forces. CD8+ cytotoxic T cells are precision special forces. Because of gene mutations, cancer cells produce abnormal proteins absent in normal cells, or overexpress certain proteins. These abnormal proteins are processed into short peptide fragments inside the cell and displayed on the cell surface through MHC-I — a process called 'antigen presentation.' CD8+ T cells scan these displayed peptide fragments through T cell receptors (TCR). If they detect a fragment not belonging to normal human proteins, the T cell is activated, identifying and killing the cell presenting this abnormal peptide.
But T cell activation can't be completed directly by tumor cells — it needs an intermediary: dendritic cells. Dendritic cells engulf apoptotic tumor cells, extract tumor antigens, then migrate to lymph nodes and present these antigens to T cells, completing T cell 'training.' Trained T cells become killers specifically recognizing specific tumor antigens, returning to the tumor site to launch attacks. This process takes time — usually days to weeks. But its advantage is high precision, and it can form immune memory.
5. The cancer-immunity cycle: the complete flow from recognition to attack
Integrating all the mechanisms above produces the 'cancer-immunity cycle' — a framework systematically summarized by Daniel S. Chen and Ira Mellman in 2013, still one of tumor immunology's most important conceptual models. This cycle includes seven steps: (1) tumor cell death, releasing tumor antigens; (2) dendritic cells capture tumor antigens; (3) dendritic cells migrate to lymph nodes, presenting antigens to T cells; (4) T cells are activated, proliferating into anti-tumor effector T cells; (5) effector T cells migrate through blood circulation to tumor sites; (6) T cells recognize antigen-MHC complexes on tumor cell surfaces; (7) T cells kill tumor cells, releasing more antigens, and the cycle starts again.
This cycle theoretically can continuously amplify anti-tumor immune responses. But in practice, cancer cells set up obstacles at multiple points in the cycle — which is what the next article (Article 68) covers: how cancer cells evade the immune system. Each cycle step is also a potential therapeutic intervention point — precisely the fundamental logic of current cancer immunotherapy research.
6. When this system fails: the beginning of immune evasion
This recognition system works very well in most cases — the vast majority of cancerous cells are cleared by NK cells or T cells before they have a chance to divide into tumors. But 'most' isn't 'all.' Some cancerous cells, through gene mutations, happen to evolve features that reduce immune system recognition efficiency: downregulating MHC-I (hiding from T cells) while upregulating certain signals to suppress NK cells; producing PD-L1 to shut off approaching T cells; or reducing danger signals (lowering NKG2D ligand expression).
These 'survivors' survived through the filtering of immune selection pressure — essentially, the immune system is unknowingly participating in a 'evolutionary selection' of cancer cells: eliminating easily recognized ones and leaving the hardest-to-recognize behind. This process is the core of the 'Immunoediting' theory's 'Escape' phase.
7. Boosting immune surveillance capacity: what you can do
Sleep's impact on NK cell activity is one of the clearest among all lifestyle-related immune factors. A 2019 study published in a Nature journal tracked healthy subjects during one week of four hours of sleep per night — NK cell activity dropped approximately seventy percent. More concerning: this decline needed several days to fully recover after resuming normal sleep. Long-term chronic sleep deprivation means immune surveillance defenses are persistently operating below seventy percent efficiency.
Regular aerobic exercise is another factor with powerful evidence supporting immune surveillance enhancement. Exercise directly mobilizes NK cells and T cells from lymphoid tissue into peripheral blood, increasing their 'patrol' frequency throughout the body. A pooled analysis tracking nearly one million people found that regular exercise was significantly associated with reduced incidence of thirteen cancer types.
Vitamin D levels also merit attention. NK cells and T cells both have vitamin D receptors; adequate vitamin D helps maintain NK cell and T cell normal function. Urban populations in East Asia (including Malaysia, Singapore, China) commonly have vitamin D deficiency — a factor worth optimizing through periodic testing and moderate supplementation.
Frequently Asked Questions